Genmab (United States)

Recent papers from Genmab (United States)

1. Industry Perspective on Current Guidelines, Challenges, and Future Directions for ADME Characterization of Payloads for Antibody‐Drug ConjugatesPharmacology Research & Perspectives · 2026
2. HexaBody-OX40 promotes antitumor immunity through FcγR crosslinking-independent OX40 agonist activity and enhances effects of PD-1 blocking antibodiesClinical Cancer Research · 2026
3. Development, implementation, and evaluation of a mentorship program within hematology/oncology pharmacy association (HOPA) - a professional oncology pharmacy organizationJournal of Oncology Pharmacy Practice · 2026
4. Quantitative Systems Pharmacology (QSP): Bridging Biology and Mechanism with Clinical Drug Development DecisionsThe Journal of Clinical Pharmacology · 2026
5. Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trialThe Lancet Haematology · 2026
6. Exposure–Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular LymphomaClinical Pharmacokinetics · 2026
7. First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphomaHemaSphere · 2026
8. Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trialInternational Journal of Gynecological Cancer · 2026
9. An In Vitro Quantitative Systems Pharmacology Platform for Characterizing CD3-Bispecific Antibody-Mediated T-Cell Activation and Tumor Cell CytotoxicityThe AAPS Journal · 2026
10. Iron homeostasis landscape informs patient survival and neoadjuvant chemotherapy response in cancerBioData Mining · 2026
11. Molecular Profiling of Tisotumab Vedotin–Treated Patients Identifies Immune Pathways Associated With Clinical ActivityClinical Cancer Research · 2026
12. Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR projectThe Journal of Liquid Biopsy · 2026
13. MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FLBlood Advances · 2026
14. Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphomaOncoImmunology · 2026
15. Epcoritamab Step‐Up Dosing Regimen Selection and Optimization Using Repeated Time‐to‐Event Modeling for Cytokine Release Syndrome Risk MitigationClinical Pharmacology & Therapeutics · 2026
16. Preclinical Comparison of Two CD3xB7H4 Bispecific Antibodies for Solid Tumor Therapy Reveals CD3 Affinity-Dependent Potency and Tolerability TradeoffsMolecular Cancer Therapeutics · 2026
17. A phase 1 dose-finding and pharmacokinetic study of acasunlimab alone or in combination with pembrolizumab in Japanese patients with advanced or metastatic solid tumorsInternational Journal of Clinical Oncology · 2026
18. Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin’s lymphomaJournal for ImmunoTherapy of Cancer · 2026
19. Multitask learning of longitudinal circulating biomarkers and clinical outcomes: identification of optimal machine-learning and deep-learning modelsBMC Medical Informatics and Decision Making · 2026
20. Genus-level oral microbiome composition and Dietary Approaches to Stop Hypertension dietary adherence in relation to hypertensionJournal of Hypertension · 2026